Q3/2024 9/30/2024 EPS -0.150 ZacksConsensus -0.130 ActVsEst (0.020) - Miss
Nuvation Bio Inc. Class A (NUVB)
Company Research
Source: Wall Street Horizon
Impact Snapshot
Event Time:
NUVB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NUVB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NUVB alerts
High impacting Nuvation Bio Inc. Class A news events
Weekly update
A roundup of the hottest topics
NUVB
News
- Nuvation Bio to Present at the Jefferies London Healthcare Conference [Yahoo! Finance]Yahoo! Finance
- Nuvation Bio to Present at the Jefferies London Healthcare ConferenceBusiness Wire
- Nuvation Bio Inc. (NYSE: NUVB) had its price target raised by analysts at Royal Bank of Canada from $5.00 to $6.00. They now have an "outperform" rating on the stock.MarketBeat
- Nuvation Bio Inc. (NYSE: NUVB) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $5.00 price target on the stock.MarketBeat
- Nuvation Bio Reports Third Quarter 2024 Financial Results and Provides Business UpdateBusiness Wire
NUVB
Earnings
- 8/5/24 - Miss
NUVB
Sec Filings
- 11/13/24 - Form 4
- 11/12/24 - Form SC
- 11/6/24 - Form 8-K
- NUVB's page on the SEC website